Neurogene Reports Highly Positive Long-Term Phase 1/2 Data for Rett Syndrome Gene Therapy NGN-401
NGNE has more than doubled off its 52-week low of $14.65 on elevated volume (3.1× avg).
Summary
Neurogene reported highly positive long-term Phase 1/2 clinical data for its NGN-401 gene therapy in Rett syndrome, showing durable developmental improvements in all participants and a strong safety profile.
Key Events · Product Development and Regulatory · NGNE
-
Positive Long-Term Phase 1/2 Clinical Data
NGN-401 gene therapy for Rett syndrome showed durable and clinically meaningful developmental milestone gains in 100% of participants, with an average of 4.7 milestones per participant and no plateau or loss of milestones through 30 months.
-
Strong Safety Profile
The 1E15 vg dose of NGN-401 was generally well-tolerated, with all treatment-related adverse events being mild or moderate, and no new treatment-related serious adverse events reported since October 2025.
-
De-risking of Registrational Trial
The Phase 1/2 response rate of 80% significantly exceeds the 33% minimum success threshold for the Embolden registrational trial, for which dosing is complete and topline data is anticipated in 2H 2027.
-
Potential for Disease-Modifying Therapy
The data suggests NGN-401 can restart developmental progression in Rett syndrome, an indication with no approved disease-modifying therapies, offering significant potential for patients.
Analysis · NGNE · Life Sciences
Neurogene announced updated, positive long-term clinical data from its Phase 1/2 trial of NGN-401 for Rett syndrome, demonstrating durable and clinically meaningful developmental milestone gains in 100% of participants. The strong efficacy and favorable safety profile significantly de-risk the ongoing Embolden registrational trial, for which dosing is complete and topline data is expected in 2H 2027. This data provides strong confidence in NGN-401's potential as a best-in-class, disease-modifying therapy for a high unmet need indication.
At the time of this filing, NGNE was trading at $33.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $506.1M. The 52-week trading range was $14.65 to $37.27. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.